Early Detection of Esophageal Cancer
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 6,864 people enrolled
- Started
- 1 Nov 2016
- Ended
- 29 Apr 2024
- Type of study
- Observational
- Record updated
- 1 May 2024
- Why it stopped
- Administratively closed by the IRBO
Who can take part
- Age
- 21 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (10)Hide the full registry criteria
Who cannot take part
- Treated for peptic ulcer disease within the past month prior to the baseline evaluation
- Currently using fluconazole or lithium
- Diagnosed cancer at any site, except non-melanoma skin cancer
- Current symptoms suggestive of an upper gastrointestinal tract malignancy, including dysphagia, odynophagia, hematemesis, or weight loss of greater than 10% body weight within the past 6 months
- Contraindications to the EGD exams, including hypersensitivity to lidocaine or iodine, uncontrolled congestive heart failure, unstable angina, bleeding disorder or severe pulmonary disease
- Contraindications to use of the intervention agents, including hypersensitivity to selenomethionine, COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides
- Acute or chronic kidney disease, liver disease, or asthma
- Other serious health condition that might preclude study completion (at the discretion of the investigators)
- Pregnant or nursing an infant
Other criteria
- INCLUSION CRITERIA:; Resident of Linxian, Henan Province, People's Republic of China; 40-69 years of age at the time of EGD screening; Visible esophageal lesions with mild or moderate squamous dysplasia found at the t(-6) EGD screening exam; Confirmation of a visible index lesion at the t(0)EGD baseline exam; Willing to abstain from chronic NSAID use (defined as greater than 3 times per week for more than 2 weeks), with the exception of low-dose aspirin (less than or equal to 100 mg per day), for the duration of the study; If a subject is female and of child-bearing potential (premenopausal or less than 2 years postmenopausal and not surgically sterile), she must be willing to use adequate contraception (abstinence, IUD, birth control pills, or spermicidal gel with diaphragm or condom) for the duration of the study; Appropriate laboratory values within 2 weeks of the baseline evaluation for:; hemoglobin greater than 11.0 g/dl; WBC greater than 3000/mm(3); platelet count greater than 100,000; creatinine less than or equal to 1.5 times the upper limit of normal; AST less than or equal to 1.5 times the upper limit of normal; Alkaline phosphatase less than or equal to 1.5 the upper limit of normal; Pregnancy test negative serum or urine (women of childbearing potential only); Only those patients with mild or moderate dysplasia based on the t(-6) histology and endoscopically visible lesions at the t(0) evaluation will be eligible for participation and inclusion in the study; To be eligible at t(0), subjects must have a confirmed, endoscopically visible lesion
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Esophageal cancer is a common malignancy with a very poor prognosis. The principal reason for its poor prognosis is that most tumors are asymptomatic and go undetected until they have spread beyond the esophageal wall and are unresectable. Significant reduction in esophageal cancer mortality will require successful strategies to diagnose and treat more cases at earlier, more curable stages of disease. A successful early detection program will require an accurate, patient-acceptable screening test, confirmatory tests that can localize precursor and early invasive lesions, and one or more curative therapies that are acceptable to asymptomatic patients. This project includes five studies designed to evaluate techniques that may be useful in such an early detection program:
Read full original descriptionShow less
1. The Cytology Sampling Study will estimate and compare the sensitivity of several cytologic samplers for identifying biopsy-proven dysplasia and cancer of the esophagus. 2. The Mucosal Staining Study will evaluate whether mucosal straining can improve endoscopic localization of esophageal dysplasia and cancer. 3. The Endoscopic Staging Study will evaluate how accurately endoscopic techniques can stage dysplasia and early invasive cancer of the esophagus. 4. The Endoscopic Therapy Pilot Study will evaluate the feasibility, safety, acceptability and preliminary efficacy of endoscopic therapies for removing or ablating focal high-grade dysplasias and early invasive cancers of the esphagus. 5. The Chemoregression Study will evaluate the ability of oral chemopreventive agents to reduce progression or cause regression of low-grade squamous dysplasia of the esophagus.
This project will be carried out in Linxian, China, a county with extraordinary rates of esophageal cancer and a correspondingly high prevalence of the asymptomatic precursor and early invasive lesions that are needed for these studies. The project will be a collaborative effort of investigators from NCI, the Cancer Institute of the Chinese Academy of Medical Sciences, and several U.S. universities.
The group in the trial
- 1
Chinese adults at high risk for esophageal cancer
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 1 May 2024